search
Back to results

Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy

Primary Purpose

Pain, Postoperative

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Ketorolac
Pregabalin
Placebo oral capsule
Saline
Sponsored by
University of Utah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pain, Postoperative focused on measuring live kidney donor, donor nephrectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients anticipating donating a kidney in a live kidney donor transplant.

Exclusion Criteria:

  • Patients not receiving a donor nephrectomy
  • Pregnant, lactating, or nursing mothers
  • Medical allergies or history that would otherwise be contraindicated for of a non-steroidal anti-inflammatory drug.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Toradol and Lyrica

    Placebo and Standard of Care

    Arm Description

    Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).

    Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.

    Outcomes

    Primary Outcome Measures

    Cumulative Narcotic Use
    Cumulative narcotic use was defined by cumulative morphine equivalents over the course of a patient's hospital course. The Washington State Agency Medical Director's Group Opioid dose calculator was used to provide a total morphine dose equivalent (MDE) for each patient while in the hospital.
    Length of Hospital Stay
    Primary outcomes include length of hospital stay (LOS).

    Secondary Outcome Measures

    Serum Creatinine Levels at One Year Post-operatively
    Renal function was evaluated by following serum creatinine levels for up to one year post-operatively.
    Bleeding Risk
    Hematocrit levels were evaluated post-operatively for up to a day post-operatively for signs of blood loss.
    Number of Patients With Urinary Retention
    Patients were evaluated post-operatively during hospital stay for instances of urinary retention.
    30 Day Mortality
    Primary outcomes include 30 day mortality post-operatively.

    Full Information

    First Posted
    September 11, 2018
    Last Updated
    July 3, 2019
    Sponsor
    University of Utah
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03669081
    Brief Title
    Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy
    Official Title
    A Prospective, Double-blind, Randomized Pilot Study Evaluating the Effects of Toradol and Lyrica Verses Placebo for Pain Control After Donor Nephrectomy (TORPEDO)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    September 20, 2016 (Actual)
    Primary Completion Date
    September 30, 2018 (Actual)
    Study Completion Date
    September 30, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Utah

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The investigators will assess how the use of toradol and pregabalin affects return to bowel function and see if there is a difference in length of hospital stay. Narcotic use can affect bowel function so the investigators hypothesize that use of Toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay.
    Detailed Description
    Perioperative pain management is a significant challenge following surgery. Many pathways contribute to perioperative pain, including nociceptive, inflammatory, and neuropathic sources. Although opioids have long been a mainstay for perioperative analgesia, other non-opioid therapies have been increasingly used as part of a multimodal analgesic regimen to provide improved pain control while minimizing opioid-related side effects TORADOL (ketorolac tromethamine), is a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level. Anecdotal evidence has shown that the use of Toradol (Ketorolac) is safe in renal surgery patients. The study team aims to further evaluate this in a pilot study specifically in the population of patient who have donated their kidney in live kidney transplants. The study team will assess how the use of toradol affects return to bowel function and see if there is a difference in length of hospital stay. Narcotic use can affect bowel function so the investigators hypothesize that use of Toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay. The study team will assess differences in visual analog pain scores and total narcotic consumption, whereas secondary endpoints of urine output, serum creatinine and hemoglobin levels to assess for efficacy and safety. Pregabalin is prescribed for neuropathic pain. In many studies, preoperative administration of pregabalin reduced postoperative morphine consumption and early postoperative pain. There will be two arms of the study including: Arm 1 (pure placebo group): Placebo oral preop then Saline placebo IV x 1 in the OR, then saline placebo IV every 6 hours for 7 doses. Arm 2: Pregabalin 75mg oral preop, then Ketorolac 30 mg IV x 1 in the OR, then ketorolac 15 mg IV every 6 hours for 7 doses. Toradol and Lyrica will be used consistent with its FDA approval in terms of dosing, route of administration, etc.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pain, Postoperative
    Keywords
    live kidney donor, donor nephrectomy

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    64 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Toradol and Lyrica
    Arm Type
    Experimental
    Arm Description
    Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
    Arm Title
    Placebo and Standard of Care
    Arm Type
    Placebo Comparator
    Arm Description
    Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
    Intervention Type
    Drug
    Intervention Name(s)
    Ketorolac
    Other Intervention Name(s)
    Toradol
    Intervention Description
    Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
    Intervention Type
    Drug
    Intervention Name(s)
    Pregabalin
    Other Intervention Name(s)
    Lyrica
    Intervention Description
    Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo oral capsule
    Intervention Description
    Placebo oral capsule was administered orally 30 minutes prior to operation.
    Intervention Type
    Drug
    Intervention Name(s)
    Saline
    Intervention Description
    Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
    Primary Outcome Measure Information:
    Title
    Cumulative Narcotic Use
    Description
    Cumulative narcotic use was defined by cumulative morphine equivalents over the course of a patient's hospital course. The Washington State Agency Medical Director's Group Opioid dose calculator was used to provide a total morphine dose equivalent (MDE) for each patient while in the hospital.
    Time Frame
    82.25 hours
    Title
    Length of Hospital Stay
    Description
    Primary outcomes include length of hospital stay (LOS).
    Time Frame
    82.25 hours
    Secondary Outcome Measure Information:
    Title
    Serum Creatinine Levels at One Year Post-operatively
    Description
    Renal function was evaluated by following serum creatinine levels for up to one year post-operatively.
    Time Frame
    1 year
    Title
    Bleeding Risk
    Description
    Hematocrit levels were evaluated post-operatively for up to a day post-operatively for signs of blood loss.
    Time Frame
    24 hours
    Title
    Number of Patients With Urinary Retention
    Description
    Patients were evaluated post-operatively during hospital stay for instances of urinary retention.
    Time Frame
    82.25 hours
    Title
    30 Day Mortality
    Description
    Primary outcomes include 30 day mortality post-operatively.
    Time Frame
    30 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients anticipating donating a kidney in a live kidney donor transplant. Exclusion Criteria: Patients not receiving a donor nephrectomy Pregnant, lactating, or nursing mothers Medical allergies or history that would otherwise be contraindicated for of a non-steroidal anti-inflammatory drug.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    30589514
    Citation
    Campsen J, Call T, Allen CM, Presson AP, Martinez E, Rofaiel G, Kim RD. Prospective, double-blind, randomized clinical trial comparing an ERAS pathway with ketorolac and pregabalin versus standard of care plus placebo during live donor nephrectomy for kidney transplant. Am J Transplant. 2019 Jun;19(6):1777-1781. doi: 10.1111/ajt.15242. Epub 2019 Jan 28.
    Results Reference
    derived

    Learn more about this trial

    Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy

    We'll reach out to this number within 24 hrs